• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assays
      • Transcreener® ADP² Kinase Assay
      • Transcreener® ADO CD73 Assay
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay
      • Transcreener® cGAMP cGAS Assay
      • Transcreener® EPIGEN SAH Methyltransferase Assay
      • Transcreener® GDP GTPase Assay Kits
      • Transcreener® UDP² Glycosyltransferase Assay Kits
      • Transcreener® 2-5A OAS Assay
    • AptaFluor® HTS Assays
      • AptaFluor® SAH Methyltransferase Assay
    • HTS Assays by Target Family
      • Kinase Assay Kits
      • ATPase Assay Kits
      • Glycosyltransferase Assay Kits
      • GTPase Assay Kits
        • GAP Assay Kits
        • GEF Assay Kits
      • Ligase and Synthetase Assay Kits
      • Methyltransferase Assay Kits
      • Phosphodiesterase Assay Kits
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
    • HTS Assays by Target
      • Adenosine Kinase Assay Kits
      • AMPK Assay Kits
      • CD39 Assay Kits
      • CD73 Assay Kits
      • cGAS Assay Kits
      • DDX3 Assay Kits
      • ENPP1 Assay Kits
      • EZH2 Assay Kits
      • IKK-beta Assay Kits
      • IRAK4 Assay Kits
      • JAK1 Assay Kits
      • JAK3 Assay Kits
      • MAPK8 Assay Kits
      • NSP13 Assay Kits
      • NUDT5 Assay Kits
      • OAS Assay Kits
      • PKR Assay Kits
      • TBK1 Assay Kits
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Innate Immunity
    • ADK Activity Assays
    • AMPK Activity Assays
    • cGAS Activity Assays
    • CD73 Activity Assays
    • CD38 Activity Assay Services
    • CD39 Activity Assays
    • DDX3 Activity Assays
    • ENPP1 Activity Assays
    • IKK-beta Activity Assays
    • IRAK4 Activity Assays
    • JAK1 Activity Assays
    • JAK3 Activity Assays
    • MAPK8 Activity Assays
    • NSP13 Activity Assays
    • OAS1 Activity Assays
    • PKR Activity Assays
    • TBK1 Activity Assays
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Using a Glycosyltransferase Activity Assay to Study Glycosylation and the Function of GTs

by Bellbrook Labs / Tuesday, 09 July 2019 / Published in Emerging Targets, HTS Assays
Glycosyltransferase Activity Assay and Lysosomal Storage Disorders

Glycosyltransferase (GT) enzymes are incredibly diverse in their abilities to catalyze the transfer of sugar molecules to protein, carbohydrate, and lipid substrates. GTs have various metabolic and regulatory roles in biology. Glycosyltransferase targets provide different areas of therapeutic potential in a wide array of disease, including cancer, metabolic disorders, and infectious disease. A glycosyltransferase activity assay provides a means of which to thoroughly interrogate GT targets for novel treatments.

From a drug discovery point of view, GTs are gaining increasing interest as targets for “substrate reduction therapy” in lysosomal storage disorders (LSDs) such as Gaucher and Fabry diseases, and as anti-microbial targets for disrupting bacterial cell wall biosynthesis. From an HTS assay perspective, GTs are a challenging target class because of the diversity of both donor and acceptor substrates.

Although GTs use a diverse mix of acceptor substrates from proteins to small molecules, the majority of human GTs use only three different nucleotide-sugars as donors: UDP, GDP, or CMP. Because there is only one “donor product” for each type of group transfer reaction, a single set of detection reagents can cover an entire family.

Studying Lysosomal Storage Disorders with a Glycosyltransferase Activity Assay

Lysosomal storage disorders (LSDs), a group of over 40 inheritable diseases present in one out of every 7700 births, arise from enzyme deficiencies within the glycosphingolipid pathway that result in toxic accumulations of non-degraded substrates. LSDs include Gaucher, Tay-Sachs, Sandhoff, Fabry, Neimann-Pick type C, and GM1 gangliosidosis diseases.

Enzyme replacement therapy (ERT) is a clinically validated treatment for some LSDs, including Gaucher and Pompe diseases, but it requires an injection of the recombinant enzyme and it is not effective for neuropathic symptoms due to the inability of the replacement enzyme to cross the blood-brain barrier.

Substrate reduction therapy (SRT) is an alternative therapeutic approach that relies on the development of small molecule inhibitors that reduce biosynthesis of the toxic metabolite. In most cases, the target enzyme is a glycosyltransferase.

Glycosyltransferase Activity Assay and LSDs

LSDs are caused by deficiencies in glycosphingolipid degradative enzymes. Inhibiting β-glucocerebrosidase (GCS) decreases flux into the biosynthetic pathway, resulting in lower levels of toxic intermediates.

Issues remain with glycosyltransferase activity assay methods. For example, measurement of activity with the traditional use of radioactive sugar-nucleotide donors, requires management of radioactive materials and waste and relies on a cumbersome extraction process to recover and measure glucosylated products. Other non-radioactive assays for glycosylated products tend to be specific for just one enzyme, can require modified sugar-nucleotide donors, and may require a separation step.

A viable alternative is UDP detection through a universal assay for any UDP-sugar glycosyltransferase. Invariably, this method has involved enzyme coupling to convert the UDP to a detectable product, such as phosphate, or coupling with UDP-glucose dehydrogenase to produce NADH before conversion to a fluorescent resazurin by diaphorase. However, these coupled assays are inherently prone to false positives from compound interference with the coupling enzymes, and thus require many additional wells for counter-screening.

Therefore, a robust, in vitro high-throughput assay targeting glycosyltransferases that enables screening of chemical libraries or optimizing leads could enhance the ability to develop inhibitors with improved therapeutic properties.

The Advantages of a Direct Detection Platform

BellBrook Labs pioneered the development of HTS-compatible assays for glycosyltransferases with the introduction of the Transcreener® UDP Glycosyltransferase Activity Assay in 2005. The Transcreener platform offers the only HTS-compatible GT assay method that relies on direct detection of reaction products. Unlike other methods, it has fewer reagents and does not depend on coupling enzymes, which can interfere with the compound screening process and increase the risk of false positives or missing a hit.

Two Reagents Do the Work

The direct detection method used by the Transcreener platform relies on the interaction between an antibody and a tracer. When the donor nucleotide displaces the tracer, a change in fluorescence enables detection. The antibody is covalently labeled with terbium (Tb) for the time-resolved Förster-resonance-energy-transfer (TR-FRET) format and unmodified for the fluorescence polarization (FP) format.

Differentiate Product from Substrate

The ability to differentiate between closely related nucleotides is a central key to the Transcreener technology—enabling detection of nucleotide products in the presence of an excess of substrate (e.g, UDP detection in the presence of excess UDP-glucose), which is a requirement for measuring enzyme initial velocity. The antibodies in Transcreener assays can resolve subtle structural differences between nucleotides, such as a single phosphate or methyl group, using a simple mix-and-read protocol. This antibody selectivity for the product nucleotide versus the substrate ranges from 150-fold to greater than 1000-fold.

Reagent Stability Compatible with HTS

Transcreener reagents are extremely robust, allowing outstanding deck and signal stability. Signal readouts from some coupled assays are limited in read times, while Transcreener fluorescent readouts can be read overnight or longer. Plates can be read long after the addition of detection reagents. This makes Transcreener a great fit for automated high throughput screening.

Learn More About the Transcreener Glycosyltransferase Assay

Tagged under: Glycosyltransferase Activity Assay, Lysosomal Storage Disorders, Transcreener UDP Assay

What you can read next

Small GTPase Modulation
Small GTPase Modulation: GDP Assays to Accelerate Discovery
PKR Inhibitor Blog
Using a PKR Inhibitor Assay in the Fight Against Viruses
Webinar Slides Available: Integrated Instrument-Reagent Platform for Screening Kinases and Methyltransferases

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • PARG in Human Immunity

    Discovering the Emerging Importance of PARG in Immunity

    Poly (ADP-ribose) glycohydrolase (PARG), along ...
  • Helicases Used in Innate Immunity

    Helicases as Powerful Tools in Innate Immunity

    Helicases are among the largest and most highly...
  • Info book on cancer and RAFK1's relation

    RAF1 & Immunity: A Future Model For Cancer Research?

    RAF1, also known as c-Raf, is a member of the R...
  • OAS1 The Cost of Host Defense

    OAS1: The Cost of Host Defense

    OAS1 (Oligoadenylate synthetase 1) is induced b...
  • Scientist Studying DDX41

    DDX41 as a Sensor, Suppressor, and Modulator

    DDX41 [DEAD (Asp-Glu-Ala-Asp) Box Polypeptide 4...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP